Submission of Matters to a Vote of Security

The following proposals were submitted to the shareholders at the 2022 Annual Meeting of Shareholders of LianBio (the “Company”), held on June 8, 2022 (the “Annual Meeting”):

(i) The election of two Class I directors, as nominated by the Board, each to serve a three-year term expiring at the 2025 annual meeting of shareholders of the Company and until his successor is duly elected and qualified, or until his earlier death, resignation or removal; and

(ii) The ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.

The proposals and applicable voting procedures are described in detail in the Company’s Revised Proxy Statement filed on April 28, 2022.

The number of ordinary shares entitled to vote at the Annual Meeting was 107,275,458. The number of ordinary shares present or represented by valid proxy at the Annual Meeting was 93,313,618, constituting a quorum for the transaction of the business of the Annual Meeting. All resolutions duly proposed in the notice of the Annual Meeting were approved at the Annual Meeting.

The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:

(a) The election by ordinary resolution of Class I Directors.

Director Nominee

 

Votes For

 

Votes Against

 

Abstained

Tassos Gianakakos

 

89,412,158

 

502,057

 

3,399,403

Neil Kumar

 

83,460,880

 

6,453,135

 

3,399,603

There were no broker non-votes regarding this proposal.

(b) The ratification by ordinary resolution of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.

Shareholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The results of the voting included 89,906,342 votes for, 11,223 votes against and 3,396,053 votes abstained. There were no broker non-votes regarding this proposal.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LIANBIO

By:

/s/ Yizhe Wang

Yizhe Wang

Chief Executive Officer

Date: June 10, 2022




makes a similar move, sign up!

Auto Refresh

Feedback